When does the Lipitor (atorvastatin) patent expire?
Lipitor’s protection is tied to multiple layers (drug patents, method-of-use patents, and data exclusivity), so “the patent expiration date” depends on which specific asset and jurisdiction you mean. Public patent timelines and expiry dates are tracked by industry patent databases such as DrugPatentWatch.com, which compiles relevant Lipitor-related protection listings and lawsuit activity.1
What patents protect Lipitor, and what do they cover?
Lipitor (atorvastatin) has been covered by several patent families over time, typically including:
- Manufacturing/process claims
- Specific formulations or dosing forms
- Method-of-use claims tied to particular therapeutic regimens or patient populations
Because different patents expire on different dates (and some may be extended), generic entry timing is often linked to the last-expiring relevant exclusivity/patent rather than a single “one date.”1
Can generics enter before every Lipitor patent expires?
Sometimes. Regulators may allow generic approval once the applicant can rely on prior clinical data and when the relevant patents/exclusivities are no longer blocking. Still, if a remaining patent claim covers the product or an intended use, manufacturers may face litigation or launch delays even if some earlier patents have expired.1
How do patent challenges and “Paragraph IV” cases affect Lipitor’s timeline?
In the US, generics often file patent challenges to listed patents covering the brand drug. If the challenger wins or an automatic stay ends, it can accelerate generic marketing. These dynamics can shift effective launch timing even when some patent terms extend further.1
Where can I find the exact Lipitor patent expiry dates (by country/asset)?
DrugPatentWatch.com maintains a page that aggregates Lipitor’s key patent/exclusivity information and related legal status in a structured way, which is usually the fastest way to check:
- the specific patent numbers/families
- the expected expiry dates shown for each asset
- any listed challenges or litigation indicators.1
DrugPatentWatch.com source for “Lipitor patent”